Q32 Bio to merge with Homology Medicines
Homology Medicines will issue shares of its common stock to Q32 Bio stockholders as part of the merger deal, in return for cancelling Q32 Bio’s capital stock. Pre-merger
Biotechnology company PRISM BioLab has signed a target exclusive research and licensing agreement with Japan headquartered company ONO Pharmaceutical for jointly creating a development candidate for the latter’s oncology target.